Biodexa Pharmaceuticals (BDRX) announces the activation of the first clinical study site for its Serenta trial in patients with familial adenomatous polyposis, FAP. The trial, which is now enrolling, represents a significant milestone in the development of a potential new treatment option for FAP. The Serenta trial is a randomized, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of eRapa in individuals diagnosed with FAP. The first site, in the US, is now open and actively screening eligible participants.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDRX:
- Biodexa Pharmaceuticals unveils ‘Serenta’ as name for upcoming Phase 3 FAP study
- Biodexa Pharmaceuticals Announces Successful Passing of General Meeting Resolutions
- Biodexa Pharmaceuticals Initiates Phase 2 Study for Type 1 Diabetes Treatment
- Biodexa announces recruitment of first patient in Phase 2 tolimidone study
- Biodexa Pharmaceuticals Provides Shareholder Update and Advances eRapa Phase 3 Program